Evidence map›Paper›PMID 32779043›Full record

ArticleMolecular and cellular biochemistry2020

Berberine attenuates Aβ-induced neuronal damage through regulating miR-188/NOS1 in Alzheimer's disease.

Manman Chen, Lu Li, Chuanqin Liu, Lina Song

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Research progress on pharmacological effects and bioavailability of berberine.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  9. Review
  10. Neuroprotective Effect ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Manman ChenDepartment of Psychiatry, Mental Health Center of Qingdao, Qingdao University, No. 299 Nanjing Road, Qingdao, 266033, Shandong, China.
Lu LiDepartment of Psychiatry, Mental Health Center of Qingdao, Qingdao University, No. 299 Nanjing Road, Qingdao, 266033, Shandong, China.
Chuanqin LiuDepartment of Psychiatry, Mental Health Center of Qingdao, Qingdao University, No. 299 Nanjing Road, Qingdao, 266033, Shandong, China.
Lina SongDepartment of Psychiatry, Mental Health Center of Qingdao, Qingdao University, No. 299 Nanjing Road, Qingdao, 266033, Shandong, China. fbyjzc@163.com.ORCID http://orcid.org/0000-0001-7027-5024

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is a public health issue worldwide. Berberine (Ber) acts as the neuroprotective role in an animal experiment of AD. MicroRNA-188 (miRNA-188) was reported to be decreased in primary hippocampal neurons of mice. However, the roles and molecular basis of Ber and miRNA-188 in the treatment of AD need to be further explored. In this study, 5 μM Ber treatment has little effect on cell viability. Ber treatment or miR-188 overexpression expedited proliferation and inhibited caspase-3 activity and apoptotic rate in amyloid-beta (Aβ)-treated BV2 and N2a cells. MiR-188 was downregulated, and nitric oxide synthase 1 (NOS1) was upregulated in Aβ-induced BV2 and N2a cells. NOS1 worked as the target of miR-188. NOS1 overturned miR-188-induced effects on cell viability, caspase-3 activity, and apoptotic rate in Aβ-induced BV2 and N2a cells. Ber mitigated neuronal damage in Aβ-induced BV2 and N2a cells by miR-188/NOS1 axis. These results suggested that Ber accelerated cell viability and suppressed caspase-3 activity and apoptotic rate possible by miR-188/NOS1 pathway, implying the treatment of Ber as an underlying effective drug for AD patients.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAnimalsBerberineCells, CulturedGene Expression RegulationHumansMiceMicrogliaMicroRNAsNeuronsNeuroprotective AgentsNitric Oxide Synthase Type ISignal TransductionAmyloid beta-PeptidesBerberineMicroRNAsMIRN188 microRNA, mouseNeuroprotective AgentsNitric Oxide Synthase Type INos1 protein, mouseAlzheimer’s diseaseApoptosisBermiR-188NOS1Proliferation

Identifiers

PMID32779043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.